BioSpace News Archive

Moderna announced that the first participant has been dosed in a Phase I trial of its HIV trimer mRNA vaccine, mRNA-1574.

After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.

Many countries around the world that appeared to have kicked COVID-19, are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2, and more COVID news.

AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.

A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.

Sanofi and Blackstone announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma.

Illumina, Inc. announced the launch of TruSight™ Oncology Comprehensive, a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient’s cancer.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced interim Phase 1 clinical data for IDE397, a potential best in class methionine adenosyltransferase 2a inhibitor.

Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2021, and provided a corporate update.

MediciNova, Inc. announced that Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28 – 30, 2022 from 9:00 a.m. - 5:00 p.m. EDT.